Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term denosumab safety in bone metastases
2009-009374-27Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of denosumab in bone metastases, multiple myeloma (MM) and Non-hematologic malignancy, sponsored by Amgen. Primary endpoint: Subject incidence of treatment-emergent adverse events. Started May 2009; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastasesmultiple myeloma (MM)Non-hematologic malignancy
Beyond the preview
Go deeper on 2009-009374-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009374-27.